Tel Aviv, February 5, 2013 – Compugen Ltd. (NASDAQ: CGEN) today announced that the Company was invited to present at the Molecular Medicine Tri-Conference 2013, at Moscone Convention Center in San Francisco, California.
Dr. John Hunter, Vice President, Antibody Research & Development at Compugen, Inc., a wholly owned subsidiary of Compugen Ltd., will participate in a session entitled Cancer Biologics: Approaches Changing the Treatment of Cancer. Dr. Hunter’s presentation entitled Predictive Drug Discovery for Novel Cancer Biologics will take place on Thursday, February 14 at 1:45 pm PST. In his talk, Dr. Hunter will demonstrate how Compugen has applied its predictive discovery platforms to identify novel immune checkpoints for targeted antibody immunotherapy in cancer. Validation data for representative targets will also be presented.
Compugen is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company’s business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen’s corporate website at www.cgen.com.
Global Media Liaison